| Drug Name |
Cevimeline hydrochloride |
| Drug ID |
BADD_D00425 |
| Description |
Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3. It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome. |
| Indications and Usage |
For the treatment of symptoms of dry mouth in patients with Sjögren's Syndrome. |
| Marketing Status |
approved |
| ATC Code |
N07AX03 |
| DrugBank ID |
DB00185
|
| KEGG ID |
D00661
|
| MeSH ID |
C059240
|
| PubChem ID |
123603
|
| TTD Drug ID |
D0Q4CS
|
| NDC Product Code |
59651-422; 66406-0269; 0054-0334; 0713-0883; 40032-999; 46014-1002; 58159-087; 63395-201; 72888-118; 0713-0937; 42973-228; 72166-012; 43386-999; 16571-657 |
| UNII |
P81Q6V85NP
|
| Synonyms |
cevimeline | 2-methyspiro(1,3-oxathiolane-5,3)quinuclidine | AF 102B, (trans)-isomer | AF-102B | AF 102B | AF102B | Evoxac | FKS 508 | FKS-508 | SNI 2011 | SNI-2011 | AF 102B, (cis-(+))-isomer | cevimeline hydrochloride |
